2017
Alzheimer’s disease : It takes two (proteins) to tango 21 May 2017
”We specifically found that both proteins mutually enhance their individual toxic effects and cause a brain dysfunction considered to be a signature of AD. This finding challenges previous polarized theories that a single protein abnormality was the major driving force of disease progression”
Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging
Link: http://publications.mcgill.ca/medenews/2016/04/20/alzheimers-disease-it-takes-two-proteins-to-tango/
Quand deux protéines conjuguent leurs efforts pour détruire notre cerveau! 20 April 2017
Nous avons constaté que les deux protéines conjuguent leurs effets toxiques individuels et provoquent ainsi un dysfonctionnement cérébral typique de la maladie d’Alzheimer. Cette découverte remet ainsi en cause des théories scientifiques opposées qui voulaient qu’une seule des deux protéines soit responsable de la progression de la maladie
– Pedro Rosa-Neto, neurologue clinicien au Douglas et professeur adjoint à l’Université McGill, départements de neurologie, de neurochirurgie et de psychiatrie, directeur adjoint du programme PRÉVENIR-Alzheimer et directeur du Laboratoire de neuroimagerie translationnelle.
Alzheimer’s disease : It takes two (proteins) to tango March 2017
McGill researchers receive over $7M to fight brain diseases of aging 23 March 2017
“The Weston Brain Institute is seriously committed to supporting ground-breaking research in neurodegeneration in Canada” “My research in inflammatory pathways underlying AD wouldn’t be possible to conduct without their incredible support and vision.”
Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging.
Weston Brain Institute announces awardees of more than $30 million in grants to fight brain diseases of aging 20 March 2017
The Early Phase Clinical Trials Program (up to $1.7m) supports Phase I and IIa clinical trials. This is an innovative funding opportunity whereby applicants have optional access to clinical trials design experts to help improve their study designs. Grantees include:
- Dr. Pedro Rosa-Neto of Douglas Hospital Research Centre: testing in a first-in-human trial the safety and efficacy of a new drug that can potentially cross the blood brain barrier and promote amyloid clearance in early Alzheimer’s disease patients.
Enigma Biomedical Group Signs Research Agreement with McGill University Research Centre for Studies in Aging 20 February 2017
“These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease. We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.”
Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging
“The ability to visualize and quantify tau in the brain will facilitate therapeutic research in the field of Alzheimer’s disease.”
Dr. Serge Gauthier, Director of the AD & Related Disorders Research Unit of the McGill University Research Center for Studies in Aging
Link: http://www.businesswire.com/news/home/20170220005696/en
Do Astrocytes Blur the PET Signal for ‘Neuronal’ Activity? 9 Feburary 2017
“This has implications for understanding what FDG PET means as an outcome measure in clinical trials. It may reflect intervention effects on astrocytes as well as neurons,”
Dr. Pedro Rosa-Neto
Link: http://www.alzforum.org/news/research-news/do-astrocytes-blur-pet-signal-neuronal-activity
